Market closed
Celcuity/$CELC
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Celcuity
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
Ticker
$CELC
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
55
Website
Celcuity Metrics
BasicAdvanced
$446M
Market cap
-
P/E ratio
-$2.61
EPS
0.75
Beta
-
Dividend rate
Price and volume
Market cap
$446M
Beta
0.75
52-week high
$22.19
52-week low
$11.51
Average daily volume
303K
Financial strength
Current ratio
10.355
Quick ratio
10.037
Long term debt to equity
64.806
Total debt to equity
64.923
Interest coverage (TTM)
-11.49%
Management effectiveness
Return on assets (TTM)
-29.06%
Return on equity (TTM)
-77.47%
Valuation
Price to book
2.98
Price to tangible book (TTM)
2.98
Price to free cash flow (TTM)
-5.795
Growth
Earnings per share change (TTM)
-4.92%
3-year earnings per share growth (CAGR)
7.92%
What the Analysts think about Celcuity
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Celcuity stock.
Celcuity Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Celcuity Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Celcuity News
AllArticlesVideos
Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium
GlobeNewsWire·1 week ago
Celcuity Inc. (CELC) Q3 2024 Earnings Call Transcript
Seeking Alpha·1 month ago
Celcuity Inc. Reports Third Quarter Financial Results and Provides Corporate Update
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Celcuity stock?
Celcuity (CELC) has a market cap of $446M as of December 21, 2024.
What is the P/E ratio for Celcuity stock?
The price to earnings (P/E) ratio for Celcuity (CELC) stock is 0 as of December 21, 2024.
Does Celcuity stock pay dividends?
No, Celcuity (CELC) stock does not pay dividends to its shareholders as of December 21, 2024.
When is the next Celcuity dividend payment date?
Celcuity (CELC) stock does not pay dividends to its shareholders.
What is the beta indicator for Celcuity?
Celcuity (CELC) has a beta rating of 0.75. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.